Laboratory Co. of America (LH) to Release Earnings on Thursday

Laboratory Co. of America (NYSE:LH) is expected to be releasing its earnings data before the market opens on Thursday, February 6th. Analysts expect Laboratory Co. of America to post earnings of $3.40 per share and revenue of $3.31 billion for the quarter. Persons that wish to register for the company’s earnings conference call can do so using this link.

Laboratory Co. of America Trading Down 0.5 %

NYSE LH opened at $246.70 on Wednesday. The company has a current ratio of 1.44, a quick ratio of 1.30 and a debt-to-equity ratio of 0.66. The company’s fifty day simple moving average is $236.14 and its 200-day simple moving average is $228.95. The stock has a market cap of $20.63 billion, a P/E ratio of 47.72, a PEG ratio of 1.86 and a beta of 1.07. Laboratory Co. of America has a 52 week low of $191.97 and a 52 week high of $258.59.

Laboratory Co. of America Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, March 12th. Shareholders of record on Thursday, February 27th will be paid a dividend of $0.72 per share. This represents a $2.88 annualized dividend and a yield of 1.17%. The ex-dividend date is Thursday, February 27th. Laboratory Co. of America’s payout ratio is currently 55.71%.

Analysts Set New Price Targets

Several equities research analysts have weighed in on the company. Robert W. Baird increased their target price on Laboratory Co. of America from $282.00 to $289.00 and gave the stock an “outperform” rating in a research report on Friday, October 25th. Hsbc Global Res raised Laboratory Co. of America from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, October 30th. UBS Group lowered their price target on Laboratory Co. of America from $293.00 to $286.00 and set a “buy” rating on the stock in a report on Tuesday, January 28th. StockNews.com lowered shares of Laboratory Co. of America from a “buy” rating to a “hold” rating in a research report on Friday, October 25th. Finally, Barclays upped their price target on shares of Laboratory Co. of America from $249.00 to $271.00 and gave the stock an “equal weight” rating in a research note on Monday. Four research analysts have rated the stock with a hold rating, twelve have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, Laboratory Co. of America has a consensus rating of “Moderate Buy” and an average target price of $263.46.

Insiders Place Their Bets

In related news, EVP Der Vaart Sandra D. Van sold 1,000 shares of the stock in a transaction on Thursday, November 21st. The stock was sold at an average price of $239.42, for a total transaction of $239,420.00. Following the completion of the sale, the executive vice president now directly owns 2,670 shares in the company, valued at approximately $639,251.40. This trade represents a 27.25 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Adam H. Schechter sold 6,189 shares of Laboratory Co. of America stock in a transaction on Monday, November 11th. The shares were sold at an average price of $243.47, for a total value of $1,506,835.83. Following the sale, the chief executive officer now directly owns 87,441 shares of the company’s stock, valued at approximately $21,289,260.27. The trade was a 6.61 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 24,572 shares of company stock worth $5,915,209. 0.85% of the stock is currently owned by company insiders.

Laboratory Co. of America Company Profile

Labcorp Holdings, Inc engages in providing medical testing services. The company was founded on April 16, 2024 and is headquartered in Burlington, NC.